P I Industries Ltd Q3 FY2023 Concall Summary

Key Takeaways

• Strong quarter, broad-based growth: Revenue grew 19% YoY with exports up 23%, while PAT surged 58% to ₹351.8 crore, driven by favourable product mix and operating leverage.
• Margins expanded and guided higher: EBITDA margin reached ~26% this quarter, and management now estimates a 23–24% sustainable range, up from prior levels, supported by mix improvement and cost control.
• Non-agchem pivot is materializing: Enquiries from non-agrochemical sectors rose to 25% of the total, and the company aims to take non-agchem contribution to ~20% of revenue in 4–5 years, with 2–3 new products commercialized next year.
• Capacity build-out accelerates: Capex is stepping up to ₹800–850 crore next year (vs. ~₹500 crore this year) to add 25–28% capacity, with two new multiproduct plants scheduled through FY25.
• What to watch next quarter: Progress on the pharma acquisition pipeline, the pace of non-agchem commercialization, and whether export-market inventory overhangs flagged by management begin to clear.

Revenue Growth & Drivers

• Export engine leads: Exports grew 23% YoY, split between 9% volume growth and 14% from price and currency, while domestic revenue grew only 2% as institutional sales stayed subdued on high channel inventory.
• New products are scaling: Products commercialized in the last 2–3 years now contribute 17–18% of export revenue, per an analyst's math, and the company aims to commercialize 4–5 new molecules each year.
• Domestic drag from inventory: Channel inventory built up after lower-than-expected Kharif uptake from adverse weather; generic products suffered while newer branded products grew. Inventory is now being consumed, a positive trend.
• Q4 domestic outlook tempered: Q4 is not a major consumption period, and the industry typically focuses on pre-placement for Kharif, so growth purely from consumption faces a natural ceiling.
• Key molecule cyclicality acknowledged: Growth in key molecules is driven by portfolio expansion, new geographies, and growing application, but demand is cyclical by nature.

Mayank Singhal: "The operating environment today is far more volatile than earlier, and the business models that have balanced exposure to clients, geographies and technologies will scale up more attractively."

Margins & Profitability

• EBITDA margin beat: Gross margin rose 73 bps to 47%, partly from cost pass-through and favourable product mix, lifting EBITDA margin to ~26% for the quarter.
• Three margin levers: Management attributes the improvement to positive product mix, operating leverage from sustained 20–25% growth, and tight control on fixed costs, with quarterly variation expected but YoY sustainability intact.
• CSM margin mechanics: The model is not a fixed per-kg margin; it shares raw material, currency and conversion cost movements transparently with partners. The benefit seen comes from improved product mix (10–12 products commercialized in 2.5 years) and operating leverage as capacity utilization rises.
• Contribution margin detail: The roughly 1-percentage-point improvement at the contribution level is coming from favourable product mix, not from any structural pricing shift.
• Freight tailwind: Freight costs were lower this quarter, providing some support, while no major forex gains appeared in other income.

Rajnish Sarna: "While there will be certainly some variation quarter-on-quarter basis depending on product mix but on a year-on-year basis, we'll be able to reasonably sustain these margin levels."

Non-Agrochemical & Pharma Strategy

• Enquiry mix shifting: Non-agchem enquiries now represent 25% of the total pipeline, and the company expects a higher share of non-agchem molecules to be commercialized in coming quarters.
• Near-term commercialization: Three commercial products are already in CSM exports, and 2–3 non-agchem products are targeted for commercialization in the next year.
• Long-term aspiration: Management aims to take non-agchem contribution to close to 20% of revenue over the next 4–5 years, with many molecules under development screened for multi-crop, multi-pest segments and wider geographies.
• Pharma entry via CRO/CDMO: The pharma foray will start with services in the CRO/CDMO model, focused on the innovator side, not generics; generics will be a value-add only in select products with a differentiated proposition.
• Acquisition pipeline active: Management is at an advanced stage of negotiations on a few pharma opportunities and will inform the market at the appropriate time. ₹67.5 crore has already been invested into PI Health Sciences for initial setup and resource augmentation.
• R&D investment underway: For quality-related requirements in specialty chemicals, PI has augmented its R&D setups and is making further investments in FY24.

Mayank Singhal: "I'm pretty sure some of the products will scale up through different weather conditions and will give some exceptional outcomes."

Capacity & Capex

• Capex step-up: This year's estimate is ~₹500 crore; next year's plan is ₹800–850 crore, which includes rollover from the current year due to plant design changes.
• Capacity addition quantified: Investments made in the last two years and planned for next year will add capacity to the tune of 25–28%.
• Two new multiproduct plants: One is scheduled for commissioning in H2 of next year, the other may come in FY25.
• Debottlenecking gains: Achieved 12%+ capacity debottlenecking of existing assets through engineering and technological solutions, extracting more output without new builds.

Balance Sheet & Cash Flow

• Operating cash flow strong: Cash flow from operating activities reached ₹995.1 crore for 9M FY23, driven by higher EBITDA and efficient net working capital management.
• Working capital tightened: Trade working capital reduced to 90 days from 103 days, reflecting improved collection and inventory efficiency.
• Debt repaid: The outstanding ECB of US\$ 25.71 million was fully repaid during the period.
• Shareholder return: The Board declared an interim dividend of ₹4.50 per share for FY22-23.
• Tax rate visibility: Full-year tax rate is expected at less than 15%, though management declined to guide on FY24-25, calling it too early.

Risks & Uncertainties

• Export inventory overhang: Management flagged a mixed scenario: in a few markets inventory pile-up exists, while in others supply challenges persist. In America and Europe, inventories should align as seasons progress, but challenges could emerge in the coming year.
• Generic pressure from China: Generic products are facing pressure from global inventory build-up, while supply from China is simultaneously opening up, creating a double headwind for that segment.
• Growth guidance conservatism: When asked if 20% growth guidance is conservative given the higher number of commercializations, management did not confirm or deny, stating only that they remain cautious of global market uncertainties and give guidance they are very confident of.

Rajnish Sarna: "We have to be mindful of these uncertainties and we always try and give a guidance with which we are very confident."

Guidance & Commitments

Key Metrics